Blood-stage malaria vaccines - recent progress and future challenges (Q37761208)

22 August 2017

1 reference

title

Blood-stage malaria vaccines - recent progress and future challenges (English)

1 reference

22 August 2017

0 references

1 reference

A L Goodman

1

1 reference

PubMed ID

20507694

22 August 2017

S J Draper

series ordinal

2

1 reference

PubMed ID

20507694

22 August 2017

language of work or name

1 reference

1 April 2010

1 reference

Annals of Tropical Medicine and Parasitology

22 August 2017

1 reference

22 August 2017

104

1 reference

22 August 2017

189-211

1 reference

22 August 2017

3

1 reference

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

22 August 2017

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Current status of Plasmodium vivax vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The development of the RTS,S malaria vaccine candidate: challenges and lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Initiative targets malaria eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Adjuvants for malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Vaccinating with the genome: a Sisyphean task?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

B cell memory to 3 Plasmodium falciparum blood-stage antigens in a malaria-endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Viruses as vaccine vectors for infectious diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Effective induction of high-titer antibodies by viral vector vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Taking social relationships seriously: lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Pre-erythrocytic malaria vaccines: towards greater efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Prime-boost vectored malaria vaccines: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Viral vectors in malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in tanzanian children aged 12-24 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The importance of human FcgammaRI in mediating protection to malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The decline in paediatric malaria admissions on the coast of Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The end of the beginning: vaccines for the next 25 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Improving vaccine delivery using novel adjuvant systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Fc-receptors and immunity to malaria: from models to vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

New horizons in adjuvants for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Apical membrane antigen 1: a malaria vaccine candidate in review

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Protection against a malaria challenge by sporozoite inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Distinct external signals trigger sequential release of apical organelles during erythrocyte invasion by malaria parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Functional analysis of the leading malaria vaccine candidate AMA-1 reveals an essential role for the cytoplasmic domain in the invasion process

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Transcriptome of axenic liver stages of Plasmodium yoelii

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F136485910X12647085215534

10.1179/136485910X12647085215534

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20507694